Mainz Biomed N.V., a leading molecular genetics diagnostic company focused on early cancer detection, is set to unveil groundbreaking results from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. The study, conducted at 21 specialized gastroenterology sites in the US, enrolled 254 clinical patients and showcased the impressive performance of a multimodal screening test.
The presentation at DDW will highlight the test’s ability to analyze a combination of biomarkers, significantly improving early detection rates for colorectal cancer and precancerous conditions. By leveraging a unique approach that combines Fecal Immunochemical Test (FIT), DNA, mRNA biomarkers, and artificial intelligence (AI)/machine learning algorithms, Mainz Biomed aims to revolutionize current colorectal cancer screening practices and ultimately reduce cancer mortality rates globally.
The session, titled NOVEL STOOL-BASED NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER AND PRECANCEROUS LESIONS BY CLASSIC FIT COMBINED WITH NUCLEIC ACID-BASED BIOMARKER SIGNATURES, is sponsored by AGA and will be presented by Kammers, L on Sunday, May 19, 2024, from 12:30 PM to 1:30 PM EDT. The key findings from the eAArly DETECT study revealed a sensitivity of 97% for colorectal cancer and 82% for advanced adenoma, demonstrating the significant improvements made in both CRC and AA detection.
Mainz Biomed’s innovative approach underscores its commitment to advancing cancer detection and prevention, with the ultimate goal of decreasing colorectal cancer incidence and mortality rates worldwide. Stay tuned for the latest developments and insights from Mainz Biomed’s transformative research at DDW 2024.
